Just three years ago, Circassia was riding high, raising £200 million ($285 million) from its initial public offering (IPO), making it the most successful European biotech stock launch ever.

Analyst James Orsborne of Stifel Nicolaus assigned a Buy rating on Circassia Pharmaceuticals (NIOX – Research Report), with a price target of ...

UK biotech Circassia has had two key decisions go in its favour with FDA, as the company continues with its efforts to rebuild its business after a series of disastrous allergy drug trial failures.

Circassia Pharmaceuticals ( (GB:NIOX)) has shared an update. Niox Group PLC, a UK-based company, has reported a change in major holdings due to Danske Bank A/S crossing a voting rights threshold.

A global leader in technology used to track maritime vessels has returned to profit and should see earnings surge a ...

The ban was introduced in Dagestan, Ingushetia, Kabardino-Balkaria, Karachai-Circassia, North Ossetia, Chechnya, Donetsk and Lugansk People’s Republics, Zaporozhye and Kherson Regions MOSCOW ...

At Sea. c. March 1944. The troopship SS Circassia steams into Port Augusta, a Sicilian harbour, in sight of Mt Etna. On board are members of No. 451 (Spitfire) Squadron RAAF, which is bound for an ...

This quality stock's smart pivot into consumer services is more than offsetting slowing demand fo ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Morrisville airway products company Circassia is breathing a sigh of relief over a decision by the giant AETNA health insurance company that one of Circassia’s key asthma products is “medically ...